-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;white-space:normal;line-height:1.
75em;min-height:1em;border-width:0px;border-style:none;border-color:initial;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;"> 544px;">
544px;text-align:justify;white-space:normal;line-height:1.
75em;min-height:1em;border-width:0px;border-style:none;border-color:initial;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;"> 544px;">On March 8, according to foreign media reports, at the 28th Conference on Retroviruses and Opportunistic Infections, Gilead Sciences announced four new four-year data from two phase III clinical studies of the AIDS triple compound drug Biktarvy.
studies prior 544px;">-naïve HIV-1 infected adults not receiving HIV medication before the conduct, it confirmed the continued efficacy and safety of Biktarvy treat HIV-1 infection in the study Biktarvy exhibit high rates of virologic suppression, and No treatment-induced drug resistance occurred.
studies prior 544px;">-naïve HIV-1 infected adults not receiving HIV medication before the conduct, it confirmed the continued efficacy and safety of Biktarvy treat HIV-1 infection in the study Biktarvy exhibit high rates of virologic suppression, and No treatment-induced drug resistance occurred.
544px;text-align:justify;white-space:normal;line-height:1.
75em;min-height:1em;border-width:0px;border-style:none;border-color:initial;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;">544px;">
544px;">
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;">
544px;text-align:justify;white-space:normal;line-height:1.
75em;border-width:0px;border-style:none;border-color:initial;background-color:#FFFFFF;box-sizing:border-box ;">
544px;">Biktarvy is an integrase chain transfer inhibitor, consisting of bictegravir (50mg), emtricitabine (200mg) and propofol tenofovir (25mg).
544px;text-align:justify;white-space:normal;line-height:1.
75em;border-width:0px;border-style:none;border-color:initial;background-color:#FFFFFF;box-sizing:border-box ;">
544px;">In two randomized, double-blind, positive-drug-controlled Phase III clinical studies of 1489 and 1490, 98% of participants who started Biktarvy treatment achieved and maintained an undetectable viral load during the four-year follow-up.
544px;">Based on retrospective sequencing of baseline samples, a subgroup analysis of patients with TDR found that, in patients with and without TDR, Biktarvy reached the same high level of durability within 144 weeks of treatment.
Inhibition rate of sex virus.
